Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.46 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.46 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.46 |
| ▸ | GAPDH | P04406 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.46 |
| ▸ | STAT6 | P42226 | 1/20 | 0.46 |
| ▸ | PI4KA | P42356 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.46 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.46 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.46 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL98800 | 1.00 | SLC29A1 (0.56) | SLC29A1ADORA3ADORA1DPP4MEN1 | |
| SCHEMBL646509 | 0.87 | BCHE (0.46) | SLC29A1ADORA3ADORA1DPP4MEN1 | |
| SCHEMBL9851706 | 0.87 | SLC29A1 (0.44) | SLC29A1ADORA3ADORA1DPP4MEN1 | |
| SCHEMBL9851713 | 0.87 | SLC29A1 (0.44) | SLC29A1ADORA3ADORA1DPP4MEN1 | |
| SCHEMBL21565111 | 0.87 | SLC29A1 (0.53) | SLC29A1ADORA3ADORA1DPP4MEN1 | |
| SCHEMBL24538657 | 0.86 | SLC29A1 (0.55) | SLC29A1ADORA3ADORA1DPP4MEN1 | |
| Cordycepin SCHEMBL21562220 | 0.86 | ADORA3 (0.63) | SLC29A1ADORA3ADORA1DPP4MEN1 | |
| Cordycepin SCHEMBL21591024 | 0.86 | ADORA3 (0.63) | SLC29A1ADORA3ADORA1DPP4MEN1 | |
| Cordycepin SCHEMBL24220702 | 0.86 | ADORA3 (0.63) | SLC29A1ADORA3ADORA1DPP4MEN1 | |
| Cordycepin SCHEMBL22081032 | 0.86 | ADORA3 (0.63) | SLC29A1ADORA3ADORA1DPP4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 204 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12312625-B2 | Engineering strain producing cordycepin and its derivative 3′-deoxyinosine, its preparation method and application | DALIAN UNIVERSITY (CN) | 2025-05-27 | — | — | US | claimed |
| US-20240344099-A1 | ENGINEERING STRAIN PRODUCING CORDYCEPIN AND ITS DERIVATIVE 3'-DEOXYINOSINE, ITS PREPARATION METHOD AND APPLICATION | DALIAN UNIVERSITY (CN) | 2024-10-17 | — | — | US | claimed |
| WO-2023206604-A1 | ENGINEERED STRAIN FOR PRODUCING CORDYCEPIN AND DERIVATIVE 3'-DEOXYINOSINE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | 大连大学 | 2023-11-02 | — | — | WO | claimed |
| CN-114921354-B | Engineering strain for producing cordycepin and derivative 3' -deoxyinosine thereof as well as preparation method and application thereof | 大连大学 | 2023-08-25 | — | — | CN | claimed |
| CN-114921354-A | Engineering strain for producing cordycepin and derivative 3' -deoxyinosine thereof as well as preparation method and application thereof | 大连大学 | 2022-08-19 | — | — | CN | claimed |
| US-11021497-B2 | Compositions and methods for synthesis of phosphorylated molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-01 | — | — | US | claimed |
| CN-107974476-B | Biotransformation method for converting cordycepin into 3' -deoxyinosine | 中国科学院沈阳应用生态研究所 | 2020-12-29 | — | — | CN | claimed |
| US-20200239500-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-07-30 | — | — | US | claimed |
| WO-2020063262-A1 | APPLICATION OF 3'-DEOXYINOSINE IN PREPARATION OF DRUG, FOOD OR HEALTH PRODUCT FOR MULTIPLE DISEASE | SHENZHEN SUNNY BIO-TECHNOLOGY.CO., LTD (CN) | 2020-04-02 | — | — | WO | claimed |
| CN-109260217-A | 3`- deoxyinosine nucleosides is in preparation for the application in a variety of disease drugs, food or health care product | 深圳松乐生物科技有限公司 | 2019-01-25 | — | — | CN | claimed |
| US-7807653-B2 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2010-10-05 | — | — | US | claimed |
| US-20070265224-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-11-15 | — | — | US | claimed |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2004-03-25 | — | — | US | claimed |
| EP-1262564-A2 | Dna sequencing by mass spectrometry | SEQUENOM, INC. (US) | 2002-12-04 | — | — | EP | claimed |
| US-6316228-B1 | Efficient synthesis of nucleosides | THE UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2001-11-13 | — | — | US | claimed |
| EP-0090417-B1 | PROCESS FOR PRODUCING 3'-DEOXYGUANOSINE | Yamasa Shoyu Kabushiki Kaisha (JP) | 1989-03-01 | — | — | EP | claimed |
| US-4594321-A | Reacting guanine derivative with phosphate | YAMASA SHOYU KABUSHIKI KAISHA (JP) | 1986-06-10 | — | — | US | claimed |
| US-4594320-A | Reacting guanine derivative with phosphate compound | YAMASA SHOYU KABUSHIKI KAISHA (JP) | 1986-06-10 | — | — | US | claimed |
| EP-0090417-A2 | Process for producing 3'-deoxyguanosine | Yamasa Shoyu Kabushiki Kaisha (JP) | 1983-10-05 | — | — | EP | claimed |
| JP-1175991-A | — | — | None | — | — | JP | disclosed |
| JP-58170493-A | — | — | None | — | — | JP | disclosed |
| JP-61146194-A | — | — | None | — | — | JP | disclosed |
| US-20260137773-A1 | ONCOLYTIC VACCINIA VIRUSES AND RECOMBINANT VIRUSES AND METHODS OF USE THEREOF | VIROMISSILE, INC. (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4727562-A1 | USE OF CD200AR-L FOR ENHANCING ADOPTIVE T-CELL THERAPY | Elias Animal Health (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260102417-A1 | COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF CANCER | KEYZELL HOLDING S L (ES) | 2026-04-16 | — | — | US | disclosed |
| US-20260097116-A1 | ONCOLYTIC VACCINIA VIRUSES AND RECOMBINANT VIRUSES AND METHODS OF USE THEREOF | VIROMISSILE, INC. (US) | 2026-04-09 | — | — | US | disclosed |
| US-12419924-B2 | Methods for combining adoptive T cell therapy with oncolytic virus adjunct therapy | TVAX BIOMEDICAL I, LLC (US) | 2025-09-23 | — | — | US | disclosed |
| US-12338464-B2 | Clonal strains of attenuated vaccinia viruses and methods of use thereof | GENELUX CORPORATION (US) | 2025-06-24 | — | — | US | disclosed |
| US-12312625-B2 | Engineering strain producing cordycepin and its derivative 3′-deoxyinosine, its preparation method and application | DALIAN UNIVERSITY (CN) | 2025-05-27 | — | — | US | disclosed |
| US-12312625-B2 | Engineering strain producing cordycepin and its derivative 3′-deoxyinosine, its preparation method and application | DALIAN UNIVERSITY (CN) | 2025-05-27 | — | — | US | disclosed |
| US-12312625-B2 | Engineering strain producing cordycepin and its derivative 3′-deoxyinosine, its preparation method and application | DALIAN UNIVERSITY (CN) | 2025-05-27 | — | — | US | disclosed |
| US-20250163096-A1 | 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | NuCana plc (GB) | 2025-05-22 | — | — | US | disclosed |
| EP-4551240-A1 | ONCOLYTIC VACCINIA VIRUSES AND RECOMBINANT VIRUSES AND METHODS OF USE THEREOF | Viromissile, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| US-20250144128-A1 | CANCER TREATMENT | NuCana plc (GB) | 2025-05-08 | — | — | US | disclosed |
| EP-4522179-A2 | CANCER TREATMENT WITH NUC-7738 | Nucana PLC (GB) | 2025-03-19 | — | — | EP | disclosed |
| EP-4504970-A1 | COMPOSITIONS AND ANALYSIS OF DEPHOSPHORYLATED OLIGORIBONUCLEOTIDES | New England Biolabs, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| US-12173368-B2 | Compositions and analysis of dephosphorylated oligoribonucleotides | NEW ENGLAND BIOLABS, INC. (US) | 2024-12-24 | — | — | US | disclosed |
| WO-2024259195-A1 | USE OF CD200AR-L FOR ENHANCING ADOPTIVE T-CELL THERAPY | ELIAS ANIMAL HEALTH (US) | 2024-12-19 | — | — | WO | disclosed |
| US-20240344099-A1 | ENGINEERING STRAIN PRODUCING CORDYCEPIN AND ITS DERIVATIVE 3'-DEOXYINOSINE, ITS PREPARATION METHOD AND APPLICATION | DALIAN UNIVERSITY (CN) | 2024-10-17 | — | — | US | disclosed |
| US-20240344099-A1 | ENGINEERING STRAIN PRODUCING CORDYCEPIN AND ITS DERIVATIVE 3'-DEOXYINOSINE, ITS PREPARATION METHOD AND APPLICATION | DALIAN UNIVERSITY (CN) | 2024-10-17 | — | — | US | disclosed |
| US-20240301485-A1 | Compositions and Analysis of Dephosphorylated Oligoribonucleotides | NEW ENGLAND BIOLABS, INC. (US) | 2024-09-12 | — | — | US | disclosed |
| US-12054510-B2 | 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compounds | NuCana plc (GB) | 2024-08-06 | — | — | US | disclosed |
| CN-117814250-A | Application of cordycepin in inhibiting seed germination and plant growth | 大连大学 | 2024-04-05 | — | — | CN | disclosed |
| WO-2024069344-A1 | COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF CANCER | Keyzell Holding S.L. (ES) | 2024-04-04 | — | — | WO | disclosed |
| US-20240033347-A1 | ONCOLYTIC VACCINIA VIRUSES AND RECOMBINANT VIRUSES AND METHODS OF USE THEREOF | VIROMISSILE, INC. (US) | 2024-02-01 | — | — | US | disclosed |
| WO-2024011250-A1 | ONCOLYTIC VACCINIA VIRUSES AND RECOMBINANT VIRUSES AND METHODS OF USE THEREOF | VIROMISSILE, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| US-11858953-B2 | Compositions and methods for synthesis of phosphorylated molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-02 | — | — | US | disclosed |
| CN-117143941-A | Method for continuously producing 3 '-deoxyadenosine-5' -mono/polyphosphoric acid by immobilized enzyme catalysis | 南京工业大学 | 2023-12-01 | — | — | CN | disclosed |
| WO-2023218202-A2 | CANCER TREATMENT | NuCana plc (GB) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023206604-A1 | ENGINEERED STRAIN FOR PRODUCING CORDYCEPIN AND DERIVATIVE 3'-DEOXYINOSINE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | 大连大学 | 2023-11-02 | — | — | WO | disclosed |
| WO-2023206604-A1 | ENGINEERED STRAIN FOR PRODUCING CORDYCEPIN AND DERIVATIVE 3'-DEOXYINOSINE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | 大连大学 | 2023-11-02 | — | — | WO | disclosed |
| CN-113717240-B | Nucleoside compound and preparation method thereof | 哈尔滨商业大学 | 2023-10-17 | — | — | CN | disclosed |
| CN-113717240-B | Nucleoside compound and preparation method thereof | 哈尔滨商业大学 | 2023-10-17 | — | — | CN | disclosed |
| WO-2023197015-A1 | COMPOSITIONS AND ANALYSIS OF DEPHOSPHORYLATED OLIGORIBONUCLEOTIDES | NEW ENGLAND BIOLABS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230287489-A1 | Compositions and Analysis of Dephosphorylated Oligoribonucleotides | NEW ENGLAND BIOLABS, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| CN-115554309-B | Pharmaceutical composition and application thereof in preparation of products for preventing and treating mental diseases and/or sub-health mental states | 南京工业大学 | 2023-09-08 | — | — | CN | disclosed |
| CN-114921354-B | Engineering strain for producing cordycepin and derivative 3' -deoxyinosine thereof as well as preparation method and application thereof | 大连大学 | 2023-08-25 | — | — | CN | disclosed |
| CN-114921354-B | Engineering strain for producing cordycepin and derivative 3' -deoxyinosine thereof as well as preparation method and application thereof | 大连大学 | 2023-08-25 | — | — | CN | disclosed |
| CN-114921354-B | Engineering strain for producing cordycepin and derivative 3' -deoxyinosine thereof as well as preparation method and application thereof | 大连大学 | 2023-08-25 | — | — | CN | disclosed |
| CN-116555273-A | Nucleoside analogue modified aptamer and application thereof | 上海大学 | 2023-08-08 | — | — | CN | disclosed |
| US-20230233631-A1 | METHODS FOR COMBINING ADOPTIVE T CELL THERAPY WITH ONCOLYTIC VIRUS ADJUNCT THERAPY | TVAX BIOMEDICAL I, LLC | 2023-07-27 | — | — | US | disclosed |
| CN-116082426-A | Cordycepin-glycyrrhizic acid derivative and application thereof in preparation of product for preventing and treating lung injury/pulmonary fibrosis | 南京生命原健康科技有限公司 | 2023-05-09 | — | — | CN | disclosed |
| US-11633442-B2 | Methods for combining adoptive T cell therapy with oncolytic virus adjunct therapy | TVAX BIOMEDICAL I, LLC (US) | 2023-04-25 | — | — | US | disclosed |
| US-20230008052-A1 | CLONAL STRAINS OF ATTENUATED VACCINIA VIRUSES AND METHODS OF USE THEREOF | GENELUX CORPORATION | 2023-01-12 | — | — | US | disclosed |
| CN-115554309-A | Pharmaceutical composition and application thereof in preparing products for preventing and treating mental diseases and/or sub-health mental states | 南京工业大学 | 2023-01-03 | — | — | CN | disclosed |
| US-20220306675-A1 | 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | NuCana plc (GB) | 2022-09-29 | — | — | US | disclosed |
| CN-114921354-A | Engineering strain for producing cordycepin and derivative 3' -deoxyinosine thereof as well as preparation method and application thereof | 大连大学 | 2022-08-19 | — | — | CN | disclosed |
| CN-114921354-A | Engineering strain for producing cordycepin and derivative 3' -deoxyinosine thereof as well as preparation method and application thereof | 大连大学 | 2022-08-19 | — | — | CN | disclosed |
| CN-114921354-A | Engineering strain for producing cordycepin and derivative 3' -deoxyinosine thereof as well as preparation method and application thereof | 大连大学 | 2022-08-19 | — | — | CN | disclosed |
| CN-114836289-A | Preparation method of cordyceps militaris wine with high cordycepin and pentostatin content | 湖北菇菇坊生态农业有限公司 | 2022-08-02 | — | — | CN | disclosed |
| US-11352387-B2 | 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compounds | NuCana plc (GB) | 2022-06-07 | — | — | US | disclosed |
| CN-114262690-A | Clonal strains of attenuated vaccinia virus and methods of use thereof | 吉恩勒克斯公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-113717240-A | Nucleoside compound and preparation method thereof | 哈尔滨商业大学 | 2021-11-30 | — | — | CN | disclosed |
| US-20210332070-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | UNIV CALIFORNIA (US) | 2021-10-28 | — | — | US | disclosed |
| US-11149254-B2 | Clonal strains of attenuated vaccinia viruses and methods of use thereof | GENELUX CORPORATION (US) | 2021-10-19 | — | — | US | disclosed |
| US-11021497-B2 | Compositions and methods for synthesis of phosphorylated molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-01 | — | — | US | disclosed |
| CN-107974476-B | Biotransformation method for converting cordycepin into 3' -deoxyinosine | 中国科学院沈阳应用生态研究所 | 2020-12-29 | — | — | CN | disclosed |
| CN-107974476-B | Biotransformation method for converting cordycepin into 3' -deoxyinosine | 中国科学院沈阳应用生态研究所 | 2020-12-29 | — | — | CN | disclosed |
| CN-107974476-B | Biotransformation method for converting cordycepin into 3' -deoxyinosine | 中国科学院沈阳应用生态研究所 | 2020-12-29 | — | — | CN | disclosed |
| US-20200353002-A1 | METHODS FOR COMBINING ADOPTIVE T CELL THERAPY WITH ONCOLYTIC VIRUS ADJUNCT THERAPY | TVAX BIOMEDICAL I, LLC | 2020-11-12 | — | — | US | disclosed |
| CN-111909231-A | 2 ' and/or 5 ' -amino acid ester phosphoramidate 3 ' -deoxyadenosine derivatives as anticancer compounds | 努卡那有限公司 | 2020-11-10 | — | — | CN | disclosed |
| CN-107207554-B | 2 ' and/or 5 ' -amino acid ester phosphoramidate 3 ' -deoxyadenosine derivatives as anticancer compounds | 努卡那有限公司 | 2020-09-11 | — | — | CN | disclosed |
| CN-109381476-B | Weight-losing pharmaceutical composition | 于录 | 2020-08-04 | — | — | CN | disclosed |
| CN-109381476-B | Weight-losing pharmaceutical composition | 于录 | 2020-08-04 | — | — | CN | disclosed |
| US-20200239500-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-07-30 | — | — | US | disclosed |
| EP-3683225-A1 | NEW 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | Nucana PLC (GB) | 2020-07-22 | — | — | EP | disclosed |
| US-20200181189-A1 | 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | NuCana plc (GB) | 2020-06-11 | — | — | US | disclosed |
| WO-2020063262-A1 | APPLICATION OF 3'-DEOXYINOSINE IN PREPARATION OF DRUG, FOOD OR HEALTH PRODUCT FOR MULTIPLE DISEASE | SHENZHEN SUNNY BIO-TECHNOLOGY.CO., LTD (CN) | 2020-04-02 | — | — | WO | disclosed |
| WO-2020063262-A1 | APPLICATION OF 3'-DEOXYINOSINE IN PREPARATION OF DRUG, FOOD OR HEALTH PRODUCT FOR MULTIPLE DISEASE | SHENZHEN SUNNY BIO-TECHNOLOGY.CO., LTD (CN) | 2020-04-02 | — | — | WO | disclosed |
| US-10584317-B2 | Modified vaccinia virus strains for use in diagnostic and therapeutic methods | GENELUX CORPORATION (US) | 2020-03-10 | — | — | US | disclosed |
| US-10570168-B2 | 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti- cancer compounds | NuCana plc (GB) | 2020-02-25 | — | — | US | disclosed |
| EP-3224268-B1 | NEW 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | NuCana plc (GB) | 2019-06-26 | — | — | EP | disclosed |
| EP-2697368-B1 | CLONAL STRAINS OF ATTENUATED VACCINIA VIRUSES AND METHODS OF USE THEREOF | GENELUX CORP (US) | 2019-06-05 | — | — | EP | disclosed |
| US-10238700-B2 | Oncolytic virus adjunct therapy with agents that increase virus infectivity | GENELUX CORPORATION (US) | 2019-03-26 | — | — | US | disclosed |
| CN-109381476-A | A kind of pharmaceutical composition of weight-reducing | 于录 | 2019-02-26 | — | — | CN | disclosed |
| US-20190038727-A1 | METHODS FOR COMBINING ADOPTIVE T CELL THERAPY WITH ONCOLYTIC VIRUS ADJUNCT THERAPY | TVAX BIOMEDICAL I, LLC | 2019-02-07 | — | — | US | disclosed |
| CN-109260217-A | 3`- deoxyinosine nucleosides is in preparation for the application in a variety of disease drugs, food or health care product | 深圳松乐生物科技有限公司 | 2019-01-25 | — | — | CN | disclosed |
| CN-109260217-A | 3`- deoxyinosine nucleosides is in preparation for the application in a variety of disease drugs, food or health care product | 深圳松乐生物科技有限公司 | 2019-01-25 | — | — | CN | disclosed |
| CN-109115931-A | The detection method of cordycepin in a kind of blood sample | 苏州旭辉检测有限公司 | 2019-01-01 | — | — | CN | disclosed |
| US-10100076-B2 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | GILEAD PHARMASSET LLC (US) | 2018-10-16 | — | — | US | disclosed |
| EP-3347473-A1 | METHODS FOR COMBINING ADOPTIVE T CELL THERAPY WITH ONCOLYTIC VIRUS ADJUNCT THERAPY | Tvax Biomedical I, LLC (US) | 2018-07-18 | — | — | EP | disclosed |
| US-20180195050-A1 | MODIFIED VACCINIA VIRUS STRAINS FOR USE IN DIAGNOSTIC AND THERAPEUTIC METHODS | GENELUX CORPORATION | 2018-07-12 | — | — | US | disclosed |
| US-9944903-B2 | Modified vaccinia virus strains for use in diagnostic and therapeutic methods | GENELUX CORPORATION (US) | 2018-04-17 | — | — | US | disclosed |
| EP-3224268-A1 | NEW 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | NuCana BioMed Limited (GB) | 2017-10-04 | — | — | EP | disclosed |
| US-20170253629-A1 | 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | NUCANA BIOMED LIMITED (GB) | 2017-09-07 | — | — | US | disclosed |
| CN-105784904-B | Determine the LC-MS method of cordycepin metabolin in hepatomicrosome | 辽宁大学 | 2017-06-16 | — | — | CN | disclosed |
| WO-2017044780-A1 | METHODS FOR COMBINING ADOPTIVE T CELL THERAPY WITH ONCOLYTIC VIRUS ADJUNCT THERAPY | TVAX BIOMEDICAL I, LLC (US) | 2017-03-16 | — | — | WO | disclosed |
| EP-2415783-B1 | Modified vaccinia virus strains for use in a diagnostic and therapeutic method | GENELUX CORP (US) | 2016-12-14 | — | — | EP | disclosed |
| US-20160339066-A1 | ONCOLYTIC VIRUS ADJUNCT THERAPY WITH AGENTS THAT INCREASE VIRUS INFECTIVITY | GENELUX CORPORATION | 2016-11-24 | — | — | US | disclosed |
| CN-105784904-A | LC-MS/MS (liquid chromatography-tandem mass spectrometry) method for determining cordycepin metabolite in liver microsome | 辽宁大学 | 2016-07-20 | — | — | CN | disclosed |
| WO-2016083830-A1 | NEW 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | NUCANA BIOMED LIMITED (GB) | 2016-06-02 | — | — | WO | disclosed |
| EP-2171071-B1 | VACCINIA VIRUS VECTORS ENCODING A SODIUM-DEPENDENT TRANSPORTER PROTEIN FOR IMAGING AND/OR TREATMENT OF TUMORS | GENELUX CORP (US) | 2015-08-05 | — | — | EP | disclosed |
| WO-2015103438-A2 | ONCOLYTIC VIRUS ADJUNCT THERAPY WITH AGENTS THAT INCREASE VIRUS INFECTIVITY | GENELUX CORPORATION (US) | 2015-07-09 | — | — | WO | disclosed |
| US-20150175976-A1 | MODIFIED VACCINIA VIRUS STRAINS FOR USE IN DIAGNOSTIC AND THERAPEUTIC METHODS | GENELUX CORPORATION | 2015-06-25 | — | — | US | disclosed |
| US-9005602-B2 | Modified vaccinia virus strains for use in diagnostic and therapeutic methods | GENELUX CORPORATION (US) | 2015-04-14 | — | — | US | disclosed |
| US-8865153-B2 | Microorganisms for imaging and/or treatment of tumors | GENELUX CORPORATION (US) | 2014-10-21 | — | — | US | disclosed |
| US-8852927-B2 | Microorganisms for imaging and/or treatment of tumors | GENELUX CORPORATION (US) | 2014-10-07 | — | — | US | disclosed |
| US-20140271549-A1 | Use of Antibiotics to Enhance Treatment With Therapeutic Viruses | GENELUX CORPORATION | 2014-09-18 | — | — | US | disclosed |
| EP-2097517-B1 | Recombinant Lister strain vaccinia virus encoding an anti-VEGF single chain antibody | GENELUX CORP (US) | 2014-06-04 | — | — | EP | disclosed |
| US-20140086976-A1 | Compositions containing protein polymers and vaccinia virus, and methods of use thereof | GENELUX CORPORATION | 2014-03-27 | — | — | US | disclosed |
| US-20140057863-A1 | MODIFIED NUCLEOSIDES FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | GILEAD SCIENCES, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| WO-2014031693-A1 | COMPOSITIONS CONTAINING PROTEIN POLYMERS AND VACCINIA VIRUS, AND METHODS OF USE THEREOF | GENELUX CORPORATION (US) | 2014-02-27 | — | — | WO | disclosed |
| EP-2697368-A2 | CLONAL STRAINS OF ATTENUATED VACCINIA VIRUSES AND METHODS OF USE THEREOF | Genelux Corporation (US) | 2014-02-19 | — | — | EP | disclosed |
| US-20130273007-A1 | Methods for attenuating virus strains for diagnostic and therapeutic uses | GENELUX CORPORATION | 2013-10-17 | — | — | US | disclosed |
| US-20130129614-A9 | Microorganisms for imaging and/or treatment of tumors | GENELUX CORPORATION | 2013-05-23 | — | — | US | disclosed |
| EP-2251015-B1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | GILEAD PHARMASSET LLC (US) | 2013-02-20 | — | — | EP | disclosed |
| US-20120308484-A1 | Clonal strains of attenuated vaccinia viruses and methods of use thereof | GENELUX CORPORATION | 2012-12-06 | — | — | US | disclosed |
| WO-2012142529-A2 | CLONAL STRAINS OF ATTENUATED VACCINIA VIRUSES AND METHODS OF USE THEREOF | GENELUX CORPORATION (US) | 2012-10-18 | — | — | WO | disclosed |
| US-20120244068-A1 | Microorganisms for imaging and/or treatment of tumors | CHEN NANHAI (US) | 2012-09-27 | — | — | US | disclosed |
| EP-2426142-A2 | Modified vaccinia virus strains for use in a diagnostic and therapeutic method | Genelux Corporation (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20120052003-A9 | MICROORGANISMS FOR PREVENTING AND TREATING NEOPLASMS ACCOMPANYING CELLULAR THERAPY | GENELUX CORPORATION | 2012-03-01 | — | — | US | disclosed |
| EP-2415783-A1 | Modified vaccinia virus strains for use in a diagnostic and therapeutic method | Genelux Corporation (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20110293527-A1 | Modified vaccinia virus strains for use in diagnostic and therapeutic methods | GENELUX CORPORATION | 2011-12-01 | — | — | US | disclosed |
| US-8066984-B2 | Modified vaccinia virus strains for use in diagnostic and therapeutic methods | GENELUX CORPORATION (US) | 2011-11-29 | — | — | US | disclosed |
| WO-2011072179-A3 | HIGH-EFFICIENCY PHOTOVOLTAIC BACK-CONTACT SOLAR CELL STRUCTURES AND MANUFACTURING METHODS USING SEMICONDUCTOR WAFERS | SOLEXEL, INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| US-8052968-B2 | Modified vaccinia virus strains for use in diagnostic and therapeutic methods | GENELUX CORPORATION (US) | 2011-11-08 | — | — | US | disclosed |
| US-20110269707-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellullar proliferation | PHARMASSET, INC. | 2011-11-03 | — | — | US | disclosed |
| CN-102146111-A | New dinucleotide compound and preparation method thereof | BEIJING RUNDEKANG MEDICAL TECH | 2011-08-10 | — | — | CN | disclosed |
| US-20110105417-A1 | Drug Conjugates | THE CURATORS OF THE UNIVERSITY OF MISSOURI | 2011-05-05 | — | — | US | disclosed |
| EP-2300023-A2 | MICROORGANISMS FOR PREVENTING AND TREATING NEOPLASMS ACCOMPANYING CELLULAR THERAPY | Genelux Corporation (US) | 2011-03-30 | — | — | EP | disclosed |
| US-20110064650-A1 | MICROORGANISMS FOR PREVENTING AND TREATING NEOPLASMS ACCOMPANYING CELLULAR THERAPY | GENELUX CORPORATION | 2011-03-17 | — | — | US | disclosed |
| EP-2251015-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | Pharmasset, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| US-7807653-B2 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2010-10-05 | — | — | US | disclosed |
| US-20100233078-A1 | Microorganisms for imaging and/or treatment of tumors | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2010-09-16 | — | — | US | disclosed |
| EP-2171071-A2 | VACCINIA VIRUS VECTORS ENCODING A SODIUM-DEPENDENT TRANSPORTER PROTEIN FOR IMAGING AND/OR TREATMENT OF TUMORS | Genelux Corporation (US) | 2010-04-07 | — | — | EP | disclosed |
| EP-0852499-B1 | THERAPEUTIC AZIDE COMPOUNDS | UNIV GEORGIA RES FOUND (US) | 2010-03-03 | — | — | EP | disclosed |
| WO-2009158633-A1 | DRUG CONJUGATES | CURATORS OF THE UNIVERSITY OF MISSOURI ON BEHALF OF THE UNIVERSITY OF MISSOURI-KANSAS CITY (US) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009139921-A2 | MICROORGANISMS FOR PREVENTING AND TREATING NEOPLASMS ACCOMPANYING CELLULAR THERAPY | GENELUX CORPORATION (US) | 2009-11-19 | — | — | WO | disclosed |
| US-7598230-B2 | For the treatment of viral infections, microbial infections, and proliferative disorders; contain di- or triphosphate moeity mimetics, such as those containing boron anions | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2009-10-06 | — | — | US | disclosed |
| EP-2097517-A2 | MODIFIED VACCINIA VIRUS STRAINS FOR USE IN DIAGNOSTIC AND THERAPEUTIC METHODS | Genelux Corporation (US) | 2009-09-09 | — | — | EP | disclosed |
| US-20090155287-A1 | Modified vaccinia virus strains for use in diagnostic and therapeutic methods | GENELUX CORPORATION | 2009-06-18 | — | — | US | disclosed |
| US-20090117034-A1 | Microorganisms for imaging and/or treatment of tumors | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-05-07 | — | — | US | disclosed |
| US-20090098529-A1 | Methods for attenuating virus strains for diagnostic and therapeutic uses | GENELUX CORPORATION | 2009-04-16 | — | — | US | disclosed |
| WO-2008156655-A9 | VACCINIA VIRUS VECTORS ENCODING A SODIUM-DEPENDENT TRANSPORTER PROTEIN FOR IMAGING AND/OR TREATMENT OF TUMORS | GENELUX CORP (US) | 2009-03-19 | — | — | WO | disclosed |
| US-20090053244-A1 | Modified vaccinia virus strains for use in diagnostic and therapeutic methods | GENELUX CORPORATION | 2009-02-26 | — | — | US | disclosed |
| WO-2008156655-A2 | VACCINIA VIRUS VECTORS ENCODING A SODIUM-DEPENDENT TRANSPORTER PROTEIN FOR IMAGING AND/OR TREATMENT OF TUMORS | GENELUX CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008100292-A2 | MODIFIED VACCINIA VIRUS STRAINS FOR USE IN DIAGNOSTIC AND THERAPEUTIC METHODS | GENELUX CORPORATION (US) | 2008-08-21 | — | — | WO | disclosed |
| US-20080070859-A1 | Compounds resistant to metabolic deactivation and methods of use | KANE ROBERT R | 2008-03-20 | — | — | US | disclosed |
| US-20070265224-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-11-15 | — | — | US | disclosed |
| US-20070259832-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-11-08 | — | — | US | disclosed |
| US-7285658-B2 | Nucleotide mimics and their prodrugs | BIOTA, INC. (US) | 2007-10-23 | — | — | US | disclosed |
| US-20060122144-A1 | Compounds resistant to metabolic deactivation and methods of use | KANE ROBERT R | 2006-06-08 | — | — | US | disclosed |
| EP-1581547-A2 | COMPOUNDS RESISTANT TO METABOLIC DEACTIVATION AND METHODS OF USE | BAYLOR UNIVERSITY (US) | 2005-10-05 | — | — | EP | disclosed |
| US-6949521-B2 | Therapeutic azide compounds | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2005-09-27 | — | — | US | disclosed |
| US-20050123533-A1 | Prodrugs activated by targeted catalytic proteins | WELLSTAT BIOCATALYSIS, LLC | 2005-06-09 | — | — | US | disclosed |
| WO-2004050678-A2 | COMPOUNDS RESISTANT TO METABOLIC DEACTIVATION AND METHODS OF USE | BAYLOR UNIVERSITY (US) | 2004-06-17 | — | — | WO | disclosed |
| EP-1411954-A2 | MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | Pharmasset Limited (BB) | 2004-04-28 | — | — | EP | disclosed |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2004-03-25 | — | — | US | disclosed |
| US-6702705-B1 | Prodrugs activated by targeted catalytic proteins | IGEN INTERNATIONAL, INC. | 2004-03-09 | — | — | US | disclosed |
| US-20030204080-A1 | Methods for producing nucleoside derivatives and intermediates therefor | AJINOMOTO CO. INC (JP) | 2003-10-30 | — | — | US | disclosed |
| US-20030096765-A1 | Prodrugs activated by targeted catalytic proteins | IGEN, INC. | 2003-05-22 | — | — | US | disclosed |
| US-20030087873-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | PHARMASSET, INC. | 2003-05-08 | — | — | US | disclosed |
| US-20030004330-A1 | Methods for producing nucleoside derivatives and intermediates therefor | AJINOMOTO CO. INC (JP) | 2003-01-02 | — | — | US | disclosed |
| US-6500946-B1 | LOW COST, SIMPLE, HIGH YIELD PRODUCTION, INCLUDING THAT OF ANTIVIRAL AGENT 9-(2,3-DIDEOXY-2-FLUORO-.BETA.-D-THREO-PENTOFURANOSYL)ADENINE (FDDA) | AJINOMOTO CO., INC. (JP) | 2002-12-31 | — | — | US | disclosed |
| WO-2002032920-A2 | MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | PHARMASSET LIMITED (BB) | 2002-04-25 | — | — | WO | disclosed |
| US-6316228-B1 | Efficient synthesis of nucleosides | THE UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2001-11-13 | — | — | US | disclosed |
| US-20010036930-A1 | Therapeutic azide compounds | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2001-11-01 | — | — | US | disclosed |
| US-6271212-B1 | MIXTURE WITH CARRIER | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC. | 2001-08-07 | — | — | US | disclosed |
| US-6258360-B1 | BENZOATE CONJUGATES; ANTITUMOR AGENTS | IGEN INTERNATIONAL, INC. | 2001-07-10 | — | — | US | disclosed |
| EP-1076691-A1 | CELLULAR AND ANIMAL MODELS FOR DISEASES ASSOCIATED WITH ALTERED MITOCHONDRIAL FUNCTION | Mitokor (US) | 2001-02-21 | — | — | EP | disclosed |
| US-6090937-A | Methods for producing nucleoside derivatives and intermediates therefor | AJINOMOTO CO., INC. (JP) | 2000-07-18 | — | — | US | disclosed |
| WO-1999055845-A1 | CELLULAR AND ANIMAL MODELS FOR DISEASES ASSOCIATED WITH ALTERED MITOCHONDRIAL FUNCTION | MITOKOR (US) | 1999-11-04 | — | — | WO | disclosed |
| EP-0945460-A1 | Methods for producing nucleoside derivatives and intermediates therefore | Ajinomoto Co., Inc. (JP) | 1999-09-29 | — | — | EP | disclosed |
| EP-0852499-A1 | THERAPEUTIC AZIDE COMPOUNDS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1998-07-15 | — | — | EP | disclosed |
| WO-1997009052-A1 | THERAPEUTIC AZIDE COMPOUNDS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1997-03-13 | — | — | WO | disclosed |
| EP-0746336-A1 | PRODRUGS ACTIVATED BY TARGETED CATALYTIC PROTEINS | IGEN, INC. (US) | 1996-12-11 | — | — | EP | disclosed |
| EP-0582157-B1 | Method of purifying nucleoside derivatives | AJINOMOTO KK (JP) | 1996-09-18 | — | — | EP | disclosed |
| EP-0746336-A4 | PRODRUGS ACTIVATED BY TARGETED CATALYTIC PROTEINS | IGEN INC (US) | 1996-07-26 | — | — | EP | disclosed |
| EP-0411158-B1 | Process for producing nucleosides by using phosphorylases obtainable from Bacillus stearothermophilus | YAMASA SHOYU KK (JP) | 1996-05-29 | — | — | EP | disclosed |
| US-5466793-A | Catalytic reducing of a nucleoside with hydrogen in the presence of palladium and recovering | AJINOMOTO CO., INC. (JP) | 1995-11-14 | — | — | US | disclosed |
| US-5290927-A | Process for preparing 2',3'-dideoxyadenosine | AJINOMOTO CO., INC. (JP) | 1994-03-01 | — | — | US | disclosed |
| EP-0582157-A1 | Method of purifying nucleoside derivatives | Ajinomoto Co., Inc. (JP) | 1994-02-09 | — | — | EP | disclosed |
| WO-1993002703-A1 | PRODRUGS ACTIVATED BY TARGETED CATALYTIC PROTEINS | IGEN, INC. (US) | 1993-02-18 | — | — | WO | disclosed |
| EP-0450102-A1 | NUCLEOSIDE DERIVATIVE | Yamasa Shoyu Kabushiki Kaisha (JP) | 1991-10-09 | — | — | EP | disclosed |
| EP-0450102-A1 | NUCLEOSIDE DERIVATIVE | Yamasa Shoyu Kabushiki Kaisha (JP) | 1991-10-09 | — | — | EP | disclosed |
| WO-1991006555-A1 | NUCLEOSIDE DERIVATIVE | YAMASA SHOYU KABUSHIKI KAISHA (JP) | 1991-05-16 | — | — | WO | disclosed |
| JP-H01175991-A | PURIFYING METHOD OF DIDEOXYINOSINE | AJINOMOTO CO INC | 1989-07-12 | — | — | JP | disclosed |
| EP-0090417-B1 | PROCESS FOR PRODUCING 3'-DEOXYGUANOSINE | Yamasa Shoyu Kabushiki Kaisha (JP) | 1989-03-01 | — | — | EP | disclosed |
| US-4767713-A | NUCLEOSIDE PHOSPHORYLASE ACTIVITY | YAMASA SHOYU KABUSHIKI KAISHA (JP) | 1988-08-30 | — | — | US | disclosed |
| JP-S61146194-A | PRODUCTION OF 3'-DEOXYGUANOSINE | YAMASA SHOYU CO LTD | 1986-07-03 | — | — | JP | disclosed |
| US-4594321-A | Reacting guanine derivative with phosphate | YAMASA SHOYU KABUSHIKI KAISHA (JP) | 1986-06-10 | — | — | US | disclosed |
| US-4594320-A | Reacting guanine derivative with phosphate compound | YAMASA SHOYU KABUSHIKI KAISHA (JP) | 1986-06-10 | — | — | US | disclosed |
| JP-S58170493-A | PREPARATION OF 3'-DEOXYGUANOSINE | YAMASA SHOYU CO LTD | 1983-10-07 | — | — | JP | disclosed |
| EP-0090417-A2 | Process for producing 3'-deoxyguanosine | Yamasa Shoyu Kabushiki Kaisha (JP) | 1983-10-05 | — | — | EP | disclosed |
| EP-0090417-A2 | Process for producing 3'-deoxyguanosine | Yamasa Shoyu Kabushiki Kaisha (JP) | 1983-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (30 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004330-A1 | Methods for producing nucleoside derivatives and intermediates therefor | DCTD, ADAR, IMPDH1 | SLC29A1 26/4885ADORA3 297/4885ADORA1 383/4885 |
| US-20260097116-A1 | ONCOLYTIC VACCINIA VIRUSES AND RECOMBINANT VIRUSES AND METHODS OF USE THEREOF | IRF3, IFNAR1, CXCL10 | SLC29A1 430/4885ADORA3 538/4885ADORA1 574/4885 |
| US-20070259832-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | SLC29A1 19/4885ADORA3 95/4885ADORA1 91/4885 |
| US-20070265224-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | SLC29A1 19/4885ADORA3 95/4885ADORA1 91/4885 |
| US-11858953-B2 | Compositions and methods for synthesis of phosphorylated molecules | PIK3CA, CHAMP1, TYMP | SLC29A1 498/4885ADORA3 729/4885ADORA1 1078/4885 |
| US-20200239500-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | PIK3CA, CHAMP1, TYMP | SLC29A1 498/4885ADORA3 729/4885ADORA1 1078/4885 |
| US-20260102417-A1 | COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF CANCER | TACR1, TACR2, NPSR1 | SLC29A1 1884/4885ADORA3 85/4885ADORA1 68/4885 |
| US-20220306675-A1 | 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | MTAP, ADA, ADORA2A | SLC29A1 83/4885ADORA3 8/4885ADORA1 16/4885 |
| US-20050123533-A1 | Prodrugs activated by targeted catalytic proteins | DNPH1, DNPEP, PNP | SLC29A1 823/4885ADORA3 2700/4885ADORA1 2436/4885 |
| US-20080070859-A1 | Compounds resistant to metabolic deactivation and methods of use | NAT1, NNMT, PNP | SLC29A1 196/4885ADORA3 571/4885ADORA1 545/4885 |
| US-20060122144-A1 | Compounds resistant to metabolic deactivation and methods of use | NAT1, NNMT, PNP | SLC29A1 196/4885ADORA3 571/4885ADORA1 545/4885 |
| US-20030096765-A1 | Prodrugs activated by targeted catalytic proteins | DNPH1, DNPEP, PNP | SLC29A1 823/4885ADORA3 2700/4885ADORA1 2436/4885 |
| US-20030204080-A1 | Methods for producing nucleoside derivatives and intermediates therefor | DCTD, ADAR, IMPDH1 | SLC29A1 26/4885ADORA3 297/4885ADORA1 383/4885 |
| US-20260137773-A1 | ONCOLYTIC VACCINIA VIRUSES AND RECOMBINANT VIRUSES AND METHODS OF USE THEREOF | CASP9, TP53, CASP2 | SLC29A1 1933/4885ADORA3 2299/4885ADORA1 2620/4885 |
| US-12054510-B2 | 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compounds | MTAP, ADA, ADORA2A | SLC29A1 82/4885ADORA3 12/4885ADORA1 18/4885 |
| US-11021497-B2 | Compositions and methods for synthesis of phosphorylated molecules | PIK3CA, CHAMP1, TYMP | SLC29A1 498/4885ADORA3 729/4885ADORA1 1078/4885 |
| US-11352387-B2 | 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compounds | MTAP, RNMT, ADA | SLC29A1 118/4885ADORA3 15/4885ADORA1 24/4885 |
| US-20250144128-A1 | CANCER TREATMENT | ENTPD1, ENTPD5, ENTPD3 | SLC29A1 46/4885ADORA3 61/4885ADORA1 69/4885 |
| US-20140057863-A1 | MODIFIED NUCLEOSIDES FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | SLC29A1, PNP, SLC29A2 | SLC29A1 1/4885ADORA3 83/4885ADORA1 231/4885 |
| US-20110269707-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellullar proliferation | PNP, ALPP, XDH | SLC29A1 13/4885ADORA3 160/4885ADORA1 254/4885 |
| US-20110105417-A1 | Drug Conjugates | ABCB1, SLCO2B1, ABCG2 | SLC29A1 23/4885ADORA3 984/4885ADORA1 1356/4885 |
| US-10570168-B2 | 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti- cancer compounds | MTAP, RNMT, ADA | SLC29A1 118/4885ADORA3 15/4885ADORA1 24/4885 |
| US-20250163096-A1 | 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | MTAP, ADA, ADORA2A | SLC29A1 83/4885ADORA3 8/4885ADORA1 16/4885 |
| US-20210332070-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | PIK3CA, CHAMP1, TYMP | SLC29A1 498/4885ADORA3 729/4885ADORA1 1078/4885 |
| US-10100076-B2 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | SLC29A1, SLC29A2, PNP | SLC29A1 1/4885ADORA3 61/4885ADORA1 111/4885 |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | SLC29A1 19/4885ADORA3 95/4885ADORA1 91/4885 |
| US-20200181189-A1 | 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | MTAP, ADA, RNMT | SLC29A1 111/4885ADORA3 14/4885ADORA1 23/4885 |
| US-20030087873-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | SLC29A1, PNP, SLC29A2 | SLC29A1 1/4885ADORA3 82/4885ADORA1 277/4885 |
| US-20170253629-A1 | 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | MTAP, ADA, RNMT | SLC29A1 111/4885ADORA3 14/4885ADORA1 23/4885 |
| US-20010036930-A1 | Therapeutic azide compounds | ADA, ADK, DCK | SLC29A1 121/4885ADORA3 29/4885ADORA1 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.